EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clonal LIMD1 loss drives PD-L1 immune evasion via ARIH1-dependent ubiquitination in lung cancer

Kunal M Shah iD, Paul T Kennedy, James Rm Black, Piotr Pawlik iD, Kevin Litchfield, Krupa Thakkar, Maria F Contreras-Gerenas, Kirsten Brooksbank, Oliver Yuan, Paul Grevitt iD, Sarah Charrot, Jeff Davies und 4 weitere

Life Science Alliance · 2026-10 · 9 (10) · e202603812

DOI: 10.26508/lsa.202603812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 07.08.2026. Verfasst von Kunal M Shah und 15 weiteren Autor:innen. Beteiligte Einrichtung: The Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK k.sha…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lung Neoplasms, LIM Domain Proteins, Immune Evasion. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, UKRI | Biotechnology and Biological Sciences Research Council, Barts Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

LIMD1, a tumour suppressor located at chromosome 3p21.3, is frequently lost in non–small-cell lung cancer, yet its role in tumour–immune interactions remains unclear. Here, we show LIMD1 loss increases PD-L1 protein abundance across multiple lung cancer models and primary airway epithelial cells. Mechanistically, LIMD1 restrains PD-L1 through post-transcriptional and post-translational mechanisms. LIMD1 loss can relieve microRNA-mediated repression of the CD274 3′UTR, and LIMD1 loss can also disrupt ARIH1-PD-L1 association, reduce PD-L1 polyubiquitination, and stabilise PD-L1 protein without a commensurate increase in CD274 transcript levels in isogenic models. Functionally, LIMD1-deficient tumour cells suppress CD8 + T-cell activation in vitro and show enhanced sensitivity to PD-1/PD-L1 blockade in tumour–PBMC co-culture assays. Analysis of TRACERx non–small-cell lung cancer samples revealed clonal LIMD1 loss of heterozygosity in ∼40% of lung adenocarcinomas, where it is associated with increased tumour PD-L1 expression. Across independent patient cohorts receiving immune checkpoint blockade, low LIMD1 expression was enriched among responders. We identify LIMD1 as a tumour-intrinsic regulator of PD-L1 turnover and suggest that tumour suppressor loss can shape immune checkpoint biology and influence immunotherapy response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenLung NeoplasmsLIM Domain ProteinsImmune EvasionHumansUbiquitinationCell Line, TumorCarcinoma, Non-Small-Cell LungGene Expression Regulation, NeoplasticAnimalsMicroRNAsCD8-Positive T-Lymphocytes

Substanzen

B7-H1 AntigenCD274 protein, humanLIM Domain ProteinsMicroRNAs

Autor:innen und Institutionen

  • The Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK k.shah@qmul.ac.uk.
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
  • North West Cancer Research Institute, North Wales Medical School, Bangor University, Bangor, UK.
  • UCL Cancer Institute, London, UK.
  • The Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.
  • The Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.

ORCID-Profile: Kunal M Shah, Piotr Pawlik, Paul Grevitt, Dimitris Lagos, Tyson V Sharp

Förderung

  • Cancer Research UK
  • UKRI | Biotechnology and Biological Sciences Research Council
  • Barts Charity
  • North West Cancer Research

Zitieren

APA

Shah, K. M., Kennedy, P. T., Black, J. R., Pawlik, P., Litchfield, K., Thakkar, K., Contreras-Gerenas, M. F., Brooksbank, K., Yuan, O., Grevitt, P., Charrot, S., Davies, J., Dahal, L. N., Lagos, D., McGranahan, N., & Sharp, T. V. (2026). Clonal LIMD1 loss drives PD-L1 immune evasion via ARIH1-dependent ubiquitination in lung cancer. Life Science Alliance, 9(10), e202603812. https://doi.org/10.26508/lsa.202603812

Vancouver

Shah KM, Kennedy PT, Black JR, Pawlik P, Litchfield K, Thakkar K, et al. Clonal LIMD1 loss drives PD-L1 immune evasion via ARIH1-dependent ubiquitination in lung cancer. Life Science Alliance. 2026;9(10):e202603812. doi:10.26508/lsa.202603812

BibTeX
@article{Shah2026,
  author = {Shah, Kunal M and Kennedy, Paul T and Black, James Rm and Pawlik, Piotr and Litchfield, Kevin and Thakkar, Krupa and Contreras-Gerenas, Maria F and Brooksbank, Kirsten and Yuan, Oliver and Grevitt, Paul and Charrot, Sarah and Davies, Jeff and Dahal, Lekh N and Lagos, Dimitris and McGranahan, Nicholas and Sharp, Tyson V},
  title = {Clonal LIMD1 loss drives PD-L1 immune evasion via ARIH1-dependent ubiquitination in lung cancer},
  journal = {Life Science Alliance},
  year = {2026},
  volume = {9},
  number = {10},
  pages = {e202603812},
  doi = {10.26508/lsa.202603812}
}
Kostenlos starten →